CAMBRIDGE, Mass. – Glympse Bio has raised $22 million in Series A funding to conduct clinical trials for a digital platform that uses bioengineered activity sensors to noninvasively detect human diseases and to monitor drug response. The financing follows an initial $6.6 million seed round in 2015. Glympse Bio is a spinoff from the laboratory of Dr. Sangeeta Bhatia at the Massachusetts Institute of Technology. “This fundraise will propel our pipeline in non-alcoholic steatohepatitis and cancer into the clinic, catalyze our product engine to address diseases with high global burden and advance partnerships with pharma for real-time monitoring of drug response in patients,” said Bhatia, in a statement. “We are delighted to have strong investment partners join in this journey to improve care for patients.” Glympse’s activity sensors are precisely bioengineered to be transported to the site of disease in patients, directly interrogate the biological activity of the diseased tissue and emit a signal that can be detected noninvasively from the recipient’s urine.
You are here: / / Glympse Bio raises $22M